Disease Overview of Diabetic Retinopathy (DR) & Diabetic Macular Edema (DME)

DR: A Common, Serious, and Undertreated Complication of Diabetes^2,3

According to the CDC, as many as 1 in 3 U.S. adults could have diabetes by 2050,⁴ which puts a great number of individuals at risk of DR
DR can affect about a third of adults over age 40 with diabetes³
DR is the leading cause of new cases of blindness among people with diabetes between the ages of 20 and 74 years²

See a
DR Severity
Scale

DME Is a Complication of DR That Can Occur Any Time⁵

Half the patients newly diagnosed with DME present with visual acuity of worse than 20/40⁶

About half the people with DR are expected to develop DME¹
Risk of DME increases with the severity of DR¹

Awareness Is Limited Among Patients With Diabetic Eye Disease⁷

The AOA states that in 2017 alone, Doctors of Optometry diagnosed >400,000 new cases of
DR.⁸ And, in a 2014 study, the majority of patients with DR or DME reported that they had
never been told by a doctor that diabetes was affecting their eyes.⁹

% Patients With DME or DR Without DME Not Told by a Doctor That Diabetes Was Affecting Their Eyes

% Patients

55%

Patients with DME

74%

Patients with DR

Cross-sectional analysis of 2005-2008 National Health and Nutrition Examination Survey (NHANES) national data; N=798 participants with self-reported diabetes stratified by DR and DME status.

There is a significant need for diabetes patient education⁹

The Majority of Patients at Risk of Vision Loss From Severe
Nonproliferative DR (NPDR) Without DME Are Not Being Treated¹⁰

In a Retrospective Analysis Conducted by Regeneron, Many Commercially Insured
Patients With DR Without DME Were Untreated 1 Year Following Diagnosis (age ≥18 years; N=9633)¹⁰

95% of patients with mild Nonproliferative Diabetic Retinopathy, 77% of patients with moderate NPDR, and 60% of patients with severe NPDR were untreated one year following diagnosis

% Patients With Untreated DR

95%

Mild NPDR

77%

Moderate NPDR

60%

Severe NPDR

Data on file—Results of a retrospective longitudinal cohort analysis of Truven MarketScan Commercial and Medicare claims data. Patients were included in the analysis if they were aged ≥18 years, had a diagnosis of diabetes, and had a diagnosis of DR without macular edema. Patients categorized according to most severe DR diagnosis (order: severe NPDR, moderate NPDR, mild NPDR). Study period: January 1, 2015, through December 31, 2015.

As an OD, you play an important role in educating patients with diabetes about modifiable
risk factors for the development and progression of DR and DME. These include¹¹:

Diet and weight
Tobacco use
Obstructive sleep apnea

High blood pressure
High cholesterol and triglyceride levels

Your Diabetes Patients May Be at Serious Risk of Vision Loss.

Learn More

AOA = American Optometric Association; CDC = Centers for Disease Control and Prevention.

See More Important Safety Information and Indications

CONTRAINDICATIONS: EYLEA^® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.

Important Safety Information and Indications

CONTRAINDICATIONS

EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.

WARNINGS AND PRECAUTIONS

Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.

ADVERSE REACTIONS

Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended for U.S. Doctors of Optometry.

References:

Diabetic Retinopathy. National Eye Institute, National Institutes of Health website. http://bit.ly/2JLRRLW. Accessed January 14, 2020.
Common Eye Disorders. Centers for Disease Control and Prevention website. http://bit.ly/2YNSBFA. Accessed January 14, 2020.
Diabetic Retinopathy. Centers for Disease Control and Prevention website. http://bit.ly/2BKTVCTS. Accessed January 14, 2020.
Number of Americans With Diabetes Projected to Double or Triple by 2050 [press release]. Centers for Disease Control and Prevention website. https://www.cdc.gov/media/
pressrel/2010/r101022.html. Accessed January 14, 2020.
Macular Edema. National Eye Institute, National Institutes of Health website. http://bit.ly/2MGKMVG. Accessed January 14, 2020.
Vestrum Health Anonymized Electronic Health Record Data.
Holekamp NM. Overview of diabetic macular edema. Am J Manag Care. 2016;22(10 suppl):s284-s291.
Diabetes and Eye Health. American Optometric Association website. http://bit.ly/2YVSGTL. Accessed January 14, 2020.
Bressler NM, Varma R, Doan QV. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(2):168-173.
Data on file. Regeneron Pharmaceuticals, Inc.
Appold K. Subscriber exclusive: tips on managing diabetic patients—developing provider relationships, educating the patient and tracking clinical signs are key. Optom Manag. May 2019. http://bit.ly/2KQPBYZ. Accessed January 14, 2020.

EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.

11/2020
EYL.20.10.0064

DISEASE OVERVIEW

Diabetic Retinopathy (DR) and Diabetic
Macular Edema (DME) can put your
patients at risk of vision loss¹

DR: A Common, Serious, and Undertreated Complication of Diabetes^2,3

See a
DR Severity
Scale

DME Is a Complication of DR That Can Occur Any Time⁵

Half the patients newly diagnosed with DME present with visual acuity of worse than 20/40⁶

Awareness Is Limited Among Patients With Diabetic Eye Disease⁷

The AOA states that in 2017 alone, Doctors of Optometry diagnosed >400,000 new cases of
DR.⁸ And, in a 2014 study, the majority of patients with DR or DME reported that they had
never been told by a doctor that diabetes was affecting their eyes.⁹

% Patients With DME or DR Without DME Not Told by a Doctor That Diabetes Was Affecting Their Eyes

There is a significant need for diabetes patient education⁹

The Majority of Patients at Risk of Vision Loss From Severe
Nonproliferative DR (NPDR) Without DME Are Not Being Treated¹⁰

In a Retrospective Analysis Conducted by Regeneron, Many Commercially Insured
Patients With DR Without DME Were Untreated 1 Year Following Diagnosis (age ≥18 years; N=9633)¹⁰

DISEASE OVERVIEW

Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) can put your patients at risk of vision loss1

DR: A Common, Serious, and Undertreated Complication of Diabetes2,3

See a DR Severity Scale

DME Is a Complication of DR That Can Occur Any Time5

Half the patients newly diagnosed with DME present with visual acuity of worse than 20/406

Awareness Is Limited Among Patients With Diabetic Eye Disease7

The AOA states that in 2017 alone, Doctors of Optometry diagnosed >400,000 new cases of DR.8 And, in a 2014 study, the majority of patients with DR or DME reported that they had never been told by a doctor that diabetes was affecting their eyes.9

% Patients With DME or DR Without DME Not Told by a Doctor That Diabetes Was Affecting Their Eyes

There is a significant need for diabetes patient education9

The Majority of Patients at Risk of Vision Loss From Severe Nonproliferative DR (NPDR) Without DME Are Not Being Treated10

In a Retrospective Analysis Conducted by Regeneron, Many Commercially Insured Patients With DR Without DME Were Untreated 1 Year Following Diagnosis (age ≥18 years; N=9633)10

Diabetic Retinopathy (DR) and Diabetic
Macular Edema (DME) can put your
patients at risk of vision loss¹

DR: A Common, Serious, and Undertreated Complication of Diabetes^2,3

See a
DR Severity
Scale

DME Is a Complication of DR That Can Occur Any Time⁵

Half the patients newly diagnosed with DME present with visual acuity of worse than 20/40⁶

Awareness Is Limited Among Patients With Diabetic Eye Disease⁷

The AOA states that in 2017 alone, Doctors of Optometry diagnosed >400,000 new cases of
DR.⁸ And, in a 2014 study, the majority of patients with DR or DME reported that they had
never been told by a doctor that diabetes was affecting their eyes.⁹

There is a significant need for diabetes patient education⁹

The Majority of Patients at Risk of Vision Loss From Severe
Nonproliferative DR (NPDR) Without DME Are Not Being Treated¹⁰

In a Retrospective Analysis Conducted by Regeneron, Many Commercially Insured
Patients With DR Without DME Were Untreated 1 Year Following Diagnosis (age ≥18 years; N=9633)¹⁰